Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind randomized trial of tivantinib (ARQ 197) vs placebo in c-MET high inoperable hepatocellular carcinoma after sorafenib
jRCT2080222351Phase 3
- Sponsor
- Kyowa Kirin
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Tivantinib arm with Placebo arm (2 arms).
02
Drugs
tivantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080222351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222351.